Cullinan Therapeutics (CGEM) EPS (Basic): 2020-2024
Historic EPS (Basic) for Cullinan Therapeutics (CGEM) over the last 5 years, with Dec 2024 value amounting to -$27.78.
- Cullinan Therapeutics' EPS (Basic) fell 4649.18% to -$28.97 in Q4 2023 from the same period last year, while for Dec 2023 it was -$32.12, marking a year-over-year decrease of 1395.16%. This contributed to the annual value of -$27.78 for FY2024, which is 13.51% up from last year.
- Latest data reveals that Cullinan Therapeutics reported EPS (Basic) of -$27.78 as of FY2024, which was up 13.51% from -$32.12 recorded in FY2023.
- Cullinan Therapeutics' EPS (Basic)'s 5-year high stood at $2.46 during FY2022, with a 5-year trough of -$32.12 in FY2023.
- For the 3-year period, Cullinan Therapeutics' EPS (Basic) averaged around -$19.15, with its median value being -$27.78 (2024).
- Per our database at Business Quant, Cullinan Therapeutics' EPS (Basic) soared by 261.84% in 2022 and then tumbled by 1,405.69% in 2023.
- Cullinan Therapeutics' EPS (Basic) (Yearly) stood at -$2.60 in 2020, then skyrocketed by 41.54% to -$1.52 in 2021, then surged by 261.84% to $2.46 in 2022, then slumped by 1,405.69% to -$32.12 in 2023, then increased by 13.51% to -$27.78 in 2024.